Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today
Key Points
Mesa Laboratories fell after reporting its Q4 fiscal 2026 results.
Sales and earnings came in below Wall Street's expected earnings, but the business did report strong growth for adjusted operating income.
- 10 stocks we like better than Mesa Laboratories ›
Mesa Laboratories (NASDAQ: MLAB) stock is getting crushed in Wednesday's trading. The life-science technologies company's share price was down 19.5% as of 3:30 p.m. ET.
Before the market opened this morning, Mesa Labs published results for the fourth quarter of its 2026 fiscal year -- a reporting period that ended March 31. While the company posted a significant beat for non-GAAP (adjusted) operating in the period, sales fell short of Wall Street's expectations.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Operating income growth hasn't been enough to stop big sell-offs
Mesa Labs recorded a loss of $0.75 per share on sales of $63.72 million in fiscal Q4. Performance in the period saw revenue fall roughly $1.48 million short of the average Wall Street analyst target. On the other hand, the company did see strong growth for adjusted operating income.
Mesa posted adjusted operating income per share of $3.30 last quarter, beating the average Wall Street analyst estimate by $1.76. Performance in the quarter marked a significant improvement over the company's adjusted operating income per share of $2.25 in the prior-year period.
What's next for Mesa Labs?
Mesa president and CEO Siddhartha Kadia is still conducting an internal review of the business and expects to be able to deliver full-year guidance with the company's fiscal Q2 report. The company says that it has seen some loosening in export controls for Peptide systems over the last month, and management sees further room for improvement when it comes to supporting growth in the product category.
Should you buy stock in Mesa Laboratories right now?
Before you buy stock in Mesa Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mesa Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $472,852!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,317,207!*
Now, it’s worth noting Stock Advisor’s total average return is 984% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 27, 2026.
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
